I. Kenis
5 Papers
83 Citations
I. Kenis is an academic researcher. The author has contributed to research in topics: Simvastatin & Trophoblast. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Simvastatin has deleterious effects on human first trimester placental explants
I. Kenis,Shelly Tartakover-Matalon,N. Cherepnin,Liat Drucker,A. Fishman,Meir Pomeranz,Michael Lishner +6 more
TL;DR: Simvastatin adversely affects human first trimester trophoblast in an in vitro human placental model and significantly decreased secretion of progesterone from the placental explants.
62
Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression
Shelly Tartakover-Matalon,N. Cherepnin,M. Kuchuk,Liat Drucker,I. Kenis,Ami Fishman,Meir Pomeranz,Michael Lishner +7 more
TL;DR: The inhibitory effect of simvastatin on trophoblast cell migration is associated with a significant decrease in the tested molecules, which probably contributes to the impaired migration.
22
#1386 Hypertension is associated with deterioration of kidney function among patients with systemic lupus erythematosus, with or without lupus nephritis
Sydney Benchetrit,Dorin Bar-Ziv,Mohamad Kabaha,I. Kenis,Oshrat E. Tayer-Shifman,Keren Cohen-Hagai +5 more
TL;DR: Hypertension is highly prevalent among Israeli patients with SLE and is associated with decreased eGFR, ESRD, heart failure and mortality.
#1720 Insights from sodium-glucose transport 2 (SGLT2) inhibitors treatment in patients with systemic lupus erythematosus
I. Kenis,Oshrat E. Tayer-Shifman,Dorin Bar-Ziv,Mohamad Kabaha,Yael Pri-Paz-Basson,Shaye Kivity,Keren Cohen-Hagai,Sydney Benchetrit +7 more
TL;DR: SGLT2i treatment in patients with SLE and kidney involvement is associated with similar rates of kidney function decline and severe infections as in controls.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
Markus P. Schlaich,Marc Bellet,Michael A. Weber,Parisa Danaietash,George L. Bakris,John M. Flack,Roland F. Dreier,M. Sassi-Sayadi,Lloyd Haskell,Krzysztof Narkiewicz,Ji-Guang Wang,Christopher M. Reid,Ivor Katz,Andrew E. Ajani,Sinjini Biswas,Murray D. Esler,Grahame J Elder,Simon D. Roger,David Colquhoun,John D. Mooney,G. De Backer,Alexandre Persu,Martin Chaumont,Jean-Marie Krzesinski,Thomas Vanabsche,Ginette Girard,L Pliamm,Ernesto L. Schiffrin,Fatima S. Merali,George K. Dresser,Michel Vallée,Shivinder S. Jolly,Stephen Chow,Ji-Gwang Wang,Jianjun Mu,Jing Yu,Hong Yuan,Yingqing Feng,Xin Zhang,Jianhong Xie,Ling Lin,Miroslav Souček,J Widimsky,Renata Cifkova,Jan Václavík,Martin Ullrych,M Lukac,Ivan Rychlik,Thomas G. Lauridsen,Ilkka Kantola,Jyrki Taurio,Olavi Ukkola,Olivier Ormezzano,Philippe Gosse,Michel Azizi,Pierre-Yves Courand,Pascal Delsart,Jean-Michel Tartière,Felix Mahfoud,Roland E. Schmieder,Johannes Stegbauer,Philipp Lurz,Michael Koziolek,Christian Otte,Nicole Toursarkissian,Constantinos Tsioufis,K. Kyfnidis,Athanasios J. Manolis,Sotirios Patsilinakos,Pantelis Zebekakis,Apostolos Karavidas,Páll Dénes,Katalin Bezzegh,Marianna Zsom,László Kovács,Yehonatan Sharabi,Mazen Elias,Ivetta Sukholutsky,Chaim Yosefy,I. Kenis,Shaul Atar,Massimo Volpe,Muiesan Maria Lorenza,Stefano Taddei,Guido Grassi,Franco Veglio,Jung Woo Son,Jang Young Kim,Joong-Il Park,Chang Hoon Lee,Hae Young Lee,Rasa Raugaliene,Jolanta E. Marcinkeviciene,R. Kavaliauskiene,Jaap Deinum,Abraham A. Kroon,Bert Jan H. van den Born,Andrzej Januszewicz,Andrzej Tykarski,J. Walczewska,Zbigniew Gaciong,Andrzej Wiecek,Marzena Chrostowska,Andrzej Kleinrok,Jan Krekora,Grzegorz Kania,Anna Podrazka-Szczepaniak,Cezary Goławski,Maciej Podziewski,Barbara Kaczmarek,G.A. Skoczylas,Andrzej Wilkolaski,I. Woźniak,Marzena Janik-Palazzolo,Barbara Rewerska,Alexandra Konradi,Yu. V. Shvarts,T B Pecherina,Konstantin Nikolaev,Gapon Liudmila,O. Orlikova,Viktor Mordovin,N. V. Petrochenkova,G. Kamalov,E. D. Kosmacheva,V. V. Tyrenko,V. I. Gorbunov,A. G. Obrezan,Tatiana Vyacheslavovna Supryadkina,Irina A Ler,O.G. Kotenko,Anatoly Kuzin,Fernando Martinez,Josep Redon,Anna Oliveras,Luis Beltran Romero,V. B. Shatylo,L Rudenko,Andrii Bazylevych,Yu.Yu. Rudyk,Oleksandr Karpenko,Mykola Stanislavchuk,Vira Tseluyko,Mykola Kushnir,E. Asanov,Yuriy Sirenko,Andriy Yagensky,David A. Collier,Pankaj Gupta,David J. Webb,Mary MacLeod,James M McLay,Aaron Peace,Samir Arora,Patricia Michelle Buchanan,Robert Sean Harris,Ronald G DeGarmo,Mario Guillen,Adam D. Karns,Joel M. Neutel,Yogesh Paliwal,Karl William Pettis,Phillip D Toth,Jeffrey M. Wayne,Bain Butcher,Philip Diller,Suzanne Oparil,D. Calhoun,Donald Brautigam,Jesse Matthew Goldman,Arash Rashidi,Nabeel Aslam,William Haley,Nabil Andrawis,Brian Lang,Randy L. Miller,James Powell,Robert Dewhurst,James Pritchard,D. Khanna,Dennis Tang,Nashwa Gabra,Jean-Ho Park,Conigliaro Jones,Cranford L. Scott,Blanca Alicia Luna,Murtaza Mussaji,Ravi Bhagwat,Michael Bauer,J M McGinty,R. Nambiar,Renee Sangrigoli,William R. Davis,William Eaves,Frank McGrew,Ahmed Hamdy Awad,E.J. Bolster,David Scott,Paramjit Kalirao,Pascal Dabel,Wesley B. Calhoun,Steven F. Gouge,Mark B. Warren,M. K. Lawrence,Aamir Jamal,Mohamed A. El-Shahawy,C. Mercado,Jayant Kumar,Pedro Velasquez-Mieyer,Robert Busch,Todd Lewis,Lisa Rich +211 more
TL;DR: Assessment of the blood pressure lowering efficacy of the dual endothelin antagonist aprocitentan in patients with resistant hypertension found it well tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40.